SCHEMBL30795459

SCHEMBL30795459

O=C(CC1(c2ccccc2)CCCC1)Nn1nc(-c2ccc(Cl)cc2)c2ccccc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
RXFP1 Q9HBX9 3/20 0.45
THRB P10828 1/20 0.45
TP53 P04637 5/20 0.45
MAPT P10636 4/20 0.45
NPSR1 Q6W5P4 2/20 0.45
GAA P10253 1/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789626 1.00 LMNA (0.49) LMNAMEN1KMT2ARXFP1THRB
SCHEMBL1785812 0.86 LMNA (0.53) LMNAMEN1KMT2ARXFP1THRB
SCHEMBL30794837 0.86 LMNA (0.53) LMNAMEN1KMT2ARXFP1THRB
SCHEMBL30795520 0.83 TP53 (0.49) LMNAMEN1KMT2ARXFP1THRB
SCHEMBL1788796 0.83 TP53 (0.49) LMNAMEN1KMT2ARXFP1THRB
SCHEMBL1785961 0.82 TP53 (0.38) LMNAMEN1KMT2ATHRBTP53
SCHEMBL30795413 0.82 TP53 (0.38) LMNAMEN1KMT2ATHRBTP53
SCHEMBL1785767 0.79 P2RX7 (0.49) LMNAMEN1KMT2ARXFP1THRB
SCHEMBL1790727 0.79 TP53 (0.39) LMNAMEN1KMT2ATHRBTP53
SCHEMBL30794839 0.79 TP53 (0.39) LMNAMEN1KMT2ATHRBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed